About Event

Be Part of the Only Event Dedicated to Accelerating ADC Manufacturing to Meet Shortened Timeframes

Across 3 days of presentation, roundtables and interactive workshops, the likes of Merck & Co., Seagen, ADC Therapeutics and AstraZeneca debated the importance of conjugatable and non-conjugatable impurity removal, navigated the filling process to overcome roadblocks with regulatory approval, outlined considerations for conjugation process characterization before PPQ and discussed phase appropriate platform approaches for drug product process development from IND to BLA.

The ADC Process Development Summit  combines technical knowledge-sharing with a highly focused and targeted audience to provide a forum of enriched discussions that will provide you with high-value and practical take-home lessons.

As manufacturing timelines get shorter, and product quality standards increase, make sure you don’t miss out on gaining first-hand insights from your peers attending these exclusive sessions.

Highlights You Missed:

Optimizing impurity removal and purification to hasten process development and ensure product quality of your ADC with AbbVie and Orum Therapeutics

Answering regulatory questions to develop a
robust process and overcome complexity the filing process with Janssen and Sutro Biopharma

Delving into the conjugation process and the necessary tools required to increase ADC production with uniform DAR and high yield with Merck & Co and Seagen

Reviewing drug product development to develop a phase appropriate platform approach from IND to BLA whilst understanding how to formulate highly
potent molecules with ImmunoGen
and ADC Therapeutics

Comparing and contrasting different formulations to select the right formulation for your Bristol-Myers Squibb

Hear Why Merck & Co Were Excited to Join Us:

I am excited to learn about challenges and solutions being developed by peer companies in ADC process development”- Philip R. Kuhl, Distinguished Scientist, Bioconjugation and Chemistry Commercialization, Merck & Co

I am excited to share experience and gain new perspectives and broaden horizons. It is also a great opportunity to meet the peer in the field.”- Xiaolin Zhang, Associate Principal Scientist in Biologics Process R&D, Merck & Co.